OptimizeRx (OPRX) Gets a Buy Rating from RBC Capital

In a report issued on February 24, Sean Dodge from RBC Capital maintained a Buy rating on OptimizeRx (OPRXResearch Report), with a price target of $100.00. The company’s shares closed last Friday at $45.19, close to its 52-week low of $37.38.

According to, Dodge is a 3-star analyst with an average return of 1.8% and a 48.7% success rate. Dodge covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, NextGen Healthcare, and GoodRx Holdings.

OptimizeRx has an analyst consensus of Strong Buy, with a price target consensus of $92.67, a 102.9% upside from current levels. In a report issued on February 16, Lake Street also maintained a Buy rating on the stock with a $76.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on OptimizeRx’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $16.12 million and net profit of $39.89K. In comparison, last year the company earned revenue of $10.52 million and had a GAAP net loss of $282.9K.

Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers EHR workflow solutions which include financial messaging, patient education, and brand messaging; and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Read More on OPRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More